Reviews Write New Review
[email protected]
John LaMattina
Former President of R&D at Pfizer; Senior Partner at PureTech Health; Director of Ligand Pharmaceuticals
John LaMattina, PhD, is a senior partner at PureTech Health and was previously President of Pfizer Global Research and Development and Senior Vice President of Pfizer, Inc. During his 30 year career at Pfizer Inc., Dr. LaMattina held positions of increasing responsibility for Pfizer Central Research, including Vice President of US Discovery Operations in 1993, Senior Vice President of Worldwide Discovery Operations in 1998 and Senior Vice President of Worldwide Development in 1999.
During Dr. LaMattina’s leadership tenure Pfizer discovered and/or developed a number of important new medicines including Tarceva, Chantix, Zoloft (PTSD), Selzentry and Lyrica along with a number of other medicines currently in late stage development for cancer, rheumatoid arthritis and pain. He is the author of numerous scientific publications and U.S. patents. In addition, Dr. LaMattina is the author of “Drug Truths: Dispelling the Myths About Pharma R&D”. Dr. LaMattina received the 1998 Boston College Alumni Award of Excellence in Science and the 2004 American Diabetes Association Award for Leadership and Commitment in the Fight Against Diabetes. He was awarded an Honorary Doctor of Science degree from the University of New Hampshire in 2007.
In 2010 he was the recipient of the American Chemical Society’s Earle B. Barnes Award for Leadership in Chemical Research Management. Dr. LaMattina received a B.S. in Chemistry from Boston College in 1971, and received a Ph.D. in Organic Chemistry from the University of New Hampshire in 1975.
He then moved on to Princeton University as a National Institutes of Health Postdoctoral Fellow in the laboratory of Professor E. C. Taylor. Dr. LaMattina serves on the Board of Directors of PureTech Health, Ziarco Pharmaceuticals, Ligand Pharmaceuticals, Vedanta Biosciences, is Chairman of the Board of Gelesis, and is a member of the Scientific Advisory Board of Trevena pharmaceuticals. He is the author of Devalued and Distrusted – Can the pharmaceutical industry restore its broken image? and an author of the Drug Truths blog at Forbes.com.
Related Speakers View all
Aida Habtezion
Chief Medical Officer of Pfizer
|
|
Greg Friberg
Vice President, Global Development for Oncology, Amgen
|
|
Dr. Joel Selanikio
Award-Winning Physician, Health & Technology Activis...
|
|
Agam Pandit
Director of Operations and Managing Partner at ADC E...
|
|
Jeffrey Bland
Founder & President of Big Bold Health
|
|
Mara Gordon
Cannabis Advocate, Entrepreneur & Researcher
|
|
Hamilton Bennett
Senior Director of Vaccine Access & Partnerships at ...
|
|
Hanneke Schuitemaker
Virologist, Global Head of Viral Vaccine Discovery &...
|
|
Jeremy Knox
Policy and Advocacy Lead, Drug-Resistant Infections,...
|
|
Andy Schmeltz
Global President and General Manager, Pfizer Oncology
|
|
Derek B. Lowe
Director in Chemical Biology Therapeutics; Author; R...
|
|
Hasini Jayatilaka
Postdoctoral Researcher at Stanford University
|
|
Jeff Jonas
Chief Innovation Officer and Director at Sage Therap...
|
|
Robin Berzin
Founder & CEO of Parsley Health
|
|
Rick Doblin
Psychedelics Researcher; Founder of the Multidiscipl...
|
|
Dr. Connie Mariano
Former White House Physician; Rear Admiral of the U....
|
|
Mark Kelley
Executive Vice President and Chief Medical Officer, ...
|
|
Mary Jo Gorman
Serial Healthcare Entrepreneur; Licensed Physician; ...
|
|
David Shaywitz
Chief Medical Officer at DNAnexus
|
|
David Moinina Sengeh
Minister Of Basic and Senior Secondary Education & C...
|